Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Adma Biologics (ADMA) over the last 11 years, with Q3 2025 value amounting to $1.4 million.

  • Adma Biologics' Non-Current Deffered Revenue fell 903.35% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 903.35%. This contributed to the annual value of $1.5 million for FY2024, which is 846.15% down from last year.
  • Per Adma Biologics' latest filing, its Non-Current Deffered Revenue stood at $1.4 million for Q3 2025, which was down 903.35% from $1.5 million recorded in Q2 2025.
  • Adma Biologics' 5-year Non-Current Deffered Revenue high stood at $2.1 million for Q1 2021, and its period low was $1.4 million during Q3 2025.
  • For the 5-year period, Adma Biologics' Non-Current Deffered Revenue averaged around $1.8 million, with its median value being $1.8 million (2023).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 641.71% in 2021, then plummeted by 903.35% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Non-Current Deffered Revenue stood at $2.0 million in 2021, then dropped by 7.23% to $1.8 million in 2022, then decreased by 7.8% to $1.7 million in 2023, then dropped by 8.46% to $1.5 million in 2024, then decreased by 6.92% to $1.4 million in 2025.
  • Its Non-Current Deffered Revenue stands at $1.4 million for Q3 2025, versus $1.5 million for Q2 2025 and $1.5 million for Q1 2025.